Catalin Mihalcioiu
Montreal, QC, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 22, 2022
Helicobacter pylori serology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitors.
Journal: Oncoimmunology
Published: July 14, 2022
Spatially mapping the immune landscape of melanoma using imaging mass cytometry.
Journal: Science immunology
Published: April 01, 2022
Impact of the 21-Gene Recurrence Score Assay on Treatment Decisions and Cost in Patients with Node-Positive Breast Cancer: A Multicenter Study in Quebec.
Journal: The oncologist
Published: January 14, 2022
Parathyroid Hormone-Related Protein Inhibition Blocks Triple-Negative Breast Cancer Expansion in Bone Through Epithelial to Mesenchymal Transition Reversal.
Journal: JBMR plus
Published: October 01, 2021
Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence.
Journal: Journal for immunotherapy of cancer
Published: September 06, 2021
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade.
Journal: Nature medicine
Published: December 01, 2020
Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 30, 2020
Enhanced Anticancer Effect of a Combination of S-adenosylmethionine (SAM) and Immune Checkpoint Inhibitor (ICPi) in a Syngeneic Mouse Model of Advanced Melanoma.
Journal: Frontiers in oncology
Published: March 23, 2020
A Unique Morphological Phenotype in Chemoresistant Triple-Negative Breast Cancer Reveals Metabolic Reprogramming and PLIN4 Expression as a Molecular Vulnerability.
Journal: Molecular cancer research : MCR
Published: March 09, 2019
Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial.
Journal: JAMA oncology
Published: November 14, 2018
Last Updated: 09/26/2026